PreGen-Plus Not Covered
Following reconsideration of the current NCD for colorectal cancer screening, CMS says it will not expand the colorectal cancer screening benefit to include coverage of PreGen-Plus, a commercially available screening DNA stool test. CMS says the Food and Drug Administration (FDA) has determined this test requires premarket review and approval. CMS says a subsequent request for reconsideration will be considered once FDA approval is obtained. You can read all about this NCD in CMS Transmittal 89, and in the MLN Matters article MM6145.